Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

WWARN is a network of research that analyses pooled data of numerous clinical trials. The sheer size of those data sets allows study groups to answer questions that couldn't be asked of a normal size clinical trial, such as the efficacy of an anti-malarial drug on malnourished or severely anaemic children. This research helps design policies to maintain the efficacy of current anti-malaria drugs, currently threatened by growing resistance.

Q: Can you tell us about your role as a Malaria Scientific Coordinator for WWARN?

Georgina Humphreys: My role is to drive the scientific output that we generate from pooled analyses of collected data. The data is from a whole network of collaborators from across the world, collected from clinical trials on anti-malarial drugs. The primary purpose is to analyse the efficacy of those drugs currently available. We do that by analysing the pooled data that is shared with all these collaborators on specific scientific questions.

Q: What are the current issues when working on Malaria?

GH: At the moment, WWARN is focusing on pooled analyses on particular areas of interest, which we are able to ask of the large data sets that we have, that couldn't be asked of a smaller clinical trial normal sized data set. For instance, some of our areas of research are on sub-populations of patients that receive anti-malarials that might be quite a small number of people in a normal size clinical trial, but when you pool together tens of thousands of patients' data you can start to tease out some of the drug efficacy questions within those minor sub-populations. For instance at the moment we are looking at particular sub-populations of children that are malnourished, or sub-populations of children with severe anaemia, and seeing how within those populations the drug is working, whether it is effective or not.

Q: Can you tell us about you research?

GH: My research is not primarily driven by me, but the whole point of WWARN is that it is a network of research. What is exciting about my role is the connection to researchers all over the world who pool together to collaborate through what we call study groups, where we ask a question, sometimes that question is generated internally but sometimes externally, that is of great relevance to the field. Last year I was lucky enough to work on the gametocytes study group. Gametocytes are a form of the parasite which are important for onward transmission from the human to the mosquito, and we pooled together over a 150 studies involving hundreds of different researchers from all over the world who had data sets where they had measured these gametocytes in the patients given an antimalarial drug. We finally published that paper which demonstrated that some of the drugs do have a different effect on gametocyte carriage in the patients, which is obviously important in terms of then onward transmission of malaria in those endemic countries.

Q: What are the most important lines of research that have developed over the last 5-10 years?

GH: For malaria the biggest challenge is about growing resistance, resistance to drugs and of course resistance to insecticides. Those are the two big challenges and the current treatment regimens that are available to those in endemic countries are the ACTs (Artemisinin Combination Therapies) and we have already seen very worrying signs of resistance to both the artemisinin and to its partner drug, in South East Asia in the greater Mekong region. At WWARN we are concentrating on trying to support researchers in the field to answer questions like "where is the best place to sample next?", "where should we be looking for the boundaries of the resistant parasite population that might be spreading?" or "is it occurring independently in different locations?", keeping monitoring up to a high enough level so that we can keep an eye on resistance and try to contain it, if possible.

Q: Why does your research matter and why should we put money in to it?

GH: The research questions that WWARN asks are extremely important and possible through these large data sets from the pooled network. It is of critical importance to maintain the last few drugs that are efficacious currently. To do that we need to have a good picture on where the drugs are working, or where it is starting to look like it is failing. That is of critical importance to the patients on the ground because that is all they have left at the moment. As you will know, the rate of new drug production is slow and there are not many in the pipeline coming along. We need to try and preserve the drugs we have got, keep them as effective as possible and try and protect those populations that are still very vulnerable to the disease.

Q: How does your research fit in to translational medicine within the department?

GH: Our research has direct impacts on policy. We have had a good example on a study group where the output of the study group led directly to a rewriting of the drug treatment guidelines because we demonstrated that the dosing regimen wasn't quite correct for the youngest children. I think also what is brilliant about the WWARN network is supporting young researchers out in the field trying to run trials, connecting with them and saying "how can we support you?", "what can we develop that you can use?". We are looking at developing tools and resources, helping to guide standardisation in data collection in new trials and helping people to progress through their careers too.

Georgina Humphreys

Malaria scientific coordinator

Dr Georgina Humphreys coordinates the WorldWide Antimalarial Resistance Network(WWARN) study groups by encouraging partner engagement and managing the data curation and development of publications. Georgina has extensive experience in malaria research, both in UK academic institutions and in the field in East Africa, and is a committed science communicator.

More podcasts related to Malaria

Bob Taylor: Primaquine for vivax and falciparum malaria

Primaquine can be used both to treat vivax malaria and to prevent the transmission of falciparum malaria from human to mosquito. A shorter and age-based primaquine regimen would reduce the burden of vivax malaria. It would also allow primaquine to be used more widely to block the transmission of falciparum malaria.

Lisa White: Mathematical modelling for tropical diseases

Mathematical modelling, particularly when combined with economical modelling, allows researchers and policy makers to determine the most effective interventions to fight infectious diseases such as malaria. We can use those models to explore ‘what ifs’ scenarios, at country or province level, save more lives and limit costs.

Ric Price: Curing Plasmodium vivax malaria

Vivax malaria used to be considered benign but is now recognised as an important cause of morbidity and mortality. Resistance to chloroquine (given to treat the parasite blood stage) is growing and ACT (artemisinin-based combination therapy) is becoming common treatment for vivax malaria. New drugs and better public health strategies can help elimination targets, anticipated for 2030.

Olivo Miotto: Genomics and global health

Genomics is the study of the complete DNA sequence, for example of a particular parasite, allowing us to analyse its evolution and the impact of human interventions. Alongside clinical date, we use genomics to identify mutations that are markers for drug resistance. Mapping out drug resistance then helps inform elimination programmes.

Frank Smithuis: Fighting malaria in Myanmar

Although malaria is decreasing in Myanmar, resistance to anti-malarials is on the rise in the region and the focus is now to treat people early, particularly in remote communities. MOCRU has set up a network of community health workers, trained and supplied with diagnostics, bednets and treatments, to help improve access to healthcare as well as produce the evidence to encourage policy changes.

Andrea Ruecker: Blocking malaria transmission

In the falciparum malaria parasite cycle, the gametocyte stages are responsible for the transmission from person to mosquito, then to other persons. A better understanding of how gametocytes respond to malaria treatments would help us block transmission and ultimately eliminate malaria.

Rob van der Pluijm: Tracking antimalarial resistance and treatment of malaria using Triple ACTs

Anti-malaria drug resistance is spreading throughout Southeast Asia and we need to find new treatments. Our researchers at MORU use a combination of artemisinin and two partner drugs instead of one. If confirmed safe and tolerable, triple artemisinin combination therapies might be a good option to treat multi-drug resistant malaria, as well as slow down the emergence and spread of anti-malarial resistance.

James Watson: Primaquine and vivax malaria

Primaquine is a drug used to eliminate vivax malaria from the liver and prevent relapses. However, it causes anaemia in patients with G6PD deficiency. A new, slightly longer regimen with increasing doses of primaquine could allow to safely treat all patients with vivax malaria.

Xin Hui Chan: Using big data to eliminate malaria

Malaria is the most important parasitic infection to still affect humans, and a safe use of antimalarial drugs is paramount. The current explosion of clinical data is causing a jungle of data; making sense of all this data will greatly help us in our fight to eliminate malaria.

Bob Snow: Malaria control in Africa

Quality data is vital to design better malaria control programmes. This project helps various African countries gather epidemiological evidence to better control malaria. Professor Bob Snow showed how sub-regional, evidence-based platforms can effectively change malaria treatment policies.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.